gsk.com (GSK) - צמיחת רווחי EPS רבעונית
Patent protection for vaccines and high R&D expenditures create a defensive moat that supports the current quarterly EPS growth rate, where the indicator reaches -22.90. GSK plc is implementing sustainable "green chemistry" and transitioning to safe propellants. Meanwhile, a portion of production and testing is outsourced to external CMOs, necessitating strict quality control.
%20%D7%A9%D7%99%D7%A0%D7%95%D7%99%20%D7%91%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_GSK_-_GSK-plc_-_Year-over-year-net-earnings-per-share-change-for-the-last-twelve-months "GSK GlaxoSmithKline plc: צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים בטווח 04.07.2022 - 11.11.2026 | 👁️GURU.Markets👁️")
פילוחי מדדים ואנליטיקה של חברת GSK plc (GSK)
Investors are verifying the reliability of GSK plc (GSK) through the dynamics of earnings per share. This quarterly EPS gap measures net income growth rates, reflecting the efficiency of capital management. The positive trend confirms the viability of the operating model. For this defensive pharma holding, this indicator smooths out macroeconomic shocks, revealing only seasonal fluctuations in vaccine sales. Peak values of the metric signal a risk of price correction.
